Therapeutic Advances in Movement Disorders.
作者信息
Tanner Caroline M, Ostrem Jill L
机构信息
Movement Disorder and Neuromodulation Center, Department of Neurology, Weill Institute for Neuroscience, University of California San Francisco, San Francisco, CA, USA.
Parkinson's Disease Research, Education and Clinical Center, San Francisco Veterans Affairs Medical Care System, San Francisco, CA, USA.
出版信息
Neurotherapeutics. 2020 Oct;17(4):1325-1330. doi: 10.1007/s13311-020-00988-2. Epub 2021 Jan 15.
Abstract
摘要
相似文献
1
Therapeutic Advances in Movement Disorders.
Neurotherapeutics. 2020 Oct;17(4):1325-1330. doi: 10.1007/s13311-020-00988-2. Epub 2021 Jan 15.
2
Chronic deep brain stimulation for movement disorders.
Adv Tech Stand Neurosurg. 1999;25:61-136; discussion 136-8. doi: 10.1007/978-3-7091-6412-9_3.
3
Clinical management of spasticity.
J Neurol Neurosurg Psychiatry. 2005 Apr;76(4):459-63. doi: 10.1136/jnnp.2004.035972.
4
Thalamic stimulation in movement disorders.
J Neurosurg. 1997 Apr;86(4):737. doi: 10.3171/jns.1997.86.4.0737.
5
Deep brain stimulation for movement disorders.
Neurol Res. 2004 Jan;26(1):9-20. doi: 10.1179/016164104773026480.
6
Immediate versus delayed electrical stimulation boosts botulinum toxin effect: A pilot study.
Mov Disord. 2011 Aug 1;26(9):1784-5. doi: 10.1002/mds.23678. Epub 2011 Apr 29.
7
New treatments for movement disorders?
Trends Pharmacol Sci. 1996 Oct;17(10):339-42. doi: 10.1016/s0165-6147(96)30018-7.
8
Thalamic stimulation for control of movement disorders.
Appl Neurophysiol. 1983;46(1-4):107-11. doi: 10.1159/000101248.
9
Coding for the use of botulinum toxin for movement disorders.
Continuum (Minneap Minn). 2013 Oct;19(5 Movement Disorders):1406-15. doi: 10.1212/01.CON.0000436164.71565.c5.
10
Mesothalamic brain stimulation for movement disorders (functional ablation of mini-discharge circuits).
Pavlov J Biol Sci. 1987 Jan-Mar;22(1):40.
引用本文的文献
1
Intrathecal tocilizumab for immune-mediated central nervous system complication after haploidentical hematopoietic stem cell transplantation in children: Two case reports.
Heliyon. 2024 Nov 13;10(22):e40356. doi: 10.1016/j.heliyon.2024.e40356. eCollection 2024 Nov 30.
本文引用的文献
1
Palliative Care for Parkinson's Spectrum Disorders: an Emerging Approach.
Neurotherapeutics. 2020 Oct;17(4):1456-1463. doi: 10.1007/s13311-020-00989-1. Epub 2021 Jan 13.
2
Treatment of Disorders of Tone and Other Considerations in Pediatric Movement Disorders.
Neurotherapeutics. 2020 Oct;17(4):1713-1723. doi: 10.1007/s13311-020-00984-6. Epub 2021 Jan 6.
3
Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned.
Neurotherapeutics. 2020 Oct;17(4):1393-1405. doi: 10.1007/s13311-020-00964-w. Epub 2020 Nov 17.
4
Approach to Cognitive Impairment in Parkinson's Disease.
Neurotherapeutics. 2020 Oct;17(4):1495-1510. doi: 10.1007/s13311-020-00963-x. Epub 2020 Nov 17.
5
Overcoming Barriers to Parkinson Disease Trial Participation: Increasing Diversity and Novel Designs for Recruitment and Retention.
Neurotherapeutics. 2020 Oct;17(4):1724-1735. doi: 10.1007/s13311-020-00960-0. Epub 2020 Nov 4.
6
Gene and Cell-Based Therapies for Parkinson's Disease: Where Are We?
Neurotherapeutics. 2020 Oct;17(4):1539-1562. doi: 10.1007/s13311-020-00940-4. Epub 2020 Oct 30.
7
Surgical Treatment of Parkinson's Disease: Devices and Lesion Approaches.
Neurotherapeutics. 2020 Oct;17(4):1525-1538. doi: 10.1007/s13311-020-00939-x. Epub 2020 Oct 28.
8
Treatment of Dystonia: Medications, Neurotoxins, Neuromodulation, and Rehabilitation.
Neurotherapeutics. 2020 Oct;17(4):1622-1644. doi: 10.1007/s13311-020-00944-0. Epub 2020 Oct 23.
9
Modulation of the Microbiome in Parkinson's Disease: Diet, Drug, Stool Transplant, and Beyond.
Neurotherapeutics. 2020 Oct;17(4):1406-1417. doi: 10.1007/s13311-020-00942-2. Epub 2020 Oct 9.
10
Sleep Issues in Parkinson's Disease and Their Management.
Neurotherapeutics. 2020 Oct;17(4):1480-1494. doi: 10.1007/s13311-020-00938-y. Epub 2020 Oct 7.
Zotero 插件